Overview
Fluosphera, a Swiss biotech startup, has secured €1.23 million in funding to enhance drug safety and efficacy testing. The funding round was led by Soulmates Ventures and a Swiss business angel, with participation from IndieBio New York. Fluosphera's patented multiplexed in vitro platform addresses limitations of traditional drug testing models by predicting drug responses using multiple human tissue models, thereby reducing costs and accelerating drug development. The new funding will support business development and integration of their platform into workflows.
Products
Loading...
Recent Deals
Investors: Soulmates Ventures, IndieBio New York
Fluosphera, a Swiss biotech startup, has secured €1.23 million in funding to enhance drug safety and efficacy testing. The funding round was led by Soulmates Ventures and a Swiss business angel, with participation from IndieBio New York. Fluosphera's patented multiplexed in vitro platform addresses limitations of traditional drug testing models by predicting drug responses using multiple human tissue models, thereby reducing costs and accelerating drug development. The new funding will support business development and integration of their platform into workflows.